UCB Is RADIANT As Bimekizumab Beats Cosentyx For Psoriasis
IL-17A And IL-17F Inhibitor Just Filed In US And Europe
The psoriasis market is crowded and fiercely competitive but the Belgian group's bimekizumab has bested Novartis's interleukin-17A behemoth Cosentyx in a head-to-head study. Whether UCB goes it alone or signs up a large partner with a large marketing budget remains to be seen.
You may also be interested in...
The Swiss major's biggest seller rose 12% in the second quarter and while COVID-19 had an impact, and competition is on the rise, Cosentyx is still outpacing the market overall in psoriasis, while rheumatology should drive future growth.
Despite COVID-19, Horizon Therapeutics has pulled off a spectacularly successful launch of its thyroid eye disease therapy, Tepezza, thanks to pre-commercial activities that led to a high level of initial patient and prescriber awareness, and market access teams securing a decent reimbursement rate.
The French company's hopes of joining Aimmune's Palforzia on the peanut allergy market soon have been shattered after US regulators issued a complete response letter to its Viaskin Peanut patch. A lot now depends on how much work DBV will have to do to satisfy the FDA.